eprintid: 3451
rev_number: 5
eprint_status: archive
userid: 6
dir: disk0/00/00/34/51
datestamp: 2016-04-13 11:54:02
lastmod: 2016-04-13 11:54:02
status_changed: 2016-04-13 11:54:02
type: article
metadata_visibility: show
creators_name: Teipel, Stefan J.
creators_name: Hampel, Harald
creators_name: Pietrini, Pietro
creators_name: Moller, Hans-Jurgen
creators_name: Rapoport, Stanley I.
creators_id: 
creators_id: 
creators_id: pietro.pietrini@imtlucca.it
creators_id: 
creators_id: 
title: PET in alzheimer's disease--From resting-state to activation studies
ispublished: pub
subjects: RC0321
divisions: CSA
full_text_status: none
abstract: Alzheimer's disease (AD) is a neurodegenerative process associated with aging. Due to the relative increase in the elderly population in industrialized countries, AD has evolved to a significant challenge for Western societies with regard to socioeconomic resources, clinical and family care and research capacities. Much progress has been made over the last years using neuroimaging methods to better understand brain structure and function in healthy aging and in AD. This article describes the influence of positron emission tomography (PET) studies on the paradigm shift towards a more functionally oriented view of the disease. Special emphasis is put on the contribution of PET to our knowledge of AD pathophysiology and on its use in clinical differential diagnosis. We examine new analysis techniques that have been implemented in recent years to interpret PET data, including discriminant and path analysis, as well as neural network modeling. In addition, we review activation paradigms that have been used in AD-PET studies since 1987. We summarize evidence about altered cognitive processing in AD derived from PET studies during subject stimulation that supports the maintenance of neuronal plasticity in early AD. We further review the differential diagnostic power of PET. In conclusion, we outline present use and future perspectives of activation PET for clinical trials in which drug efficacy in AD can be predicted and monitored. © 1999 Prous Science. All rights reserved.
date: 1999
publication: Drug News & Perspectives
volume: 12
number: 2
pagerange: 83
id_number: doi:10.1358/dnp.1999.12.2.863623
refereed: TRUE
issn: 0214-0934
official_url: http://doi.org/10.1358/dnp.1999.12.2.863623
citation:   Teipel, Stefan J. and Hampel, Harald and Pietrini, Pietro and Moller, Hans-Jurgen and Rapoport, Stanley I.  PET in alzheimer's disease--From resting-state to activation studies.  Drug News & Perspectives, 12 (2).  p. 83.  ISSN 0214-0934      (1999)